financetom
Business
financetom
/
Business
/
Expect revenue to reach Rs 2,000 crore this fiscal year: HEG
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Expect revenue to reach Rs 2,000 crore this fiscal year: HEG
Nov 10, 2021 8:26 AM

HEG's revenue should be around Rs 2,000 crore this year, Executive Director Manish Gulati told CNBC-TV18. Its revenue was at about Rs 1,250 crore in FY21.

The graphite electrodes maker maintained capacity utilisation of 90 percent in the June and September quarters, with improvement mostly on account of pricing. The company saw price growth of 20 percent in Q2FY22 sequentially, he said.

Also Read:

HEG shares jump 13% post robust Q2 earnings; top gainer on Nifty500

Speaking on volumes and pricing, he said, “Considering our order book and the prospects, we expect to close the year with 90 percent capacity utilisation. And about the pricing, as we move on quarter by quarter, we might see an increase of anywhere between eight percent and 10 percent.”

The company's margins should come in at similar or slightly better levels going forward, he said. “I would hazard the guess that they will be at a similar level; they should not decline but we should be able to pass on the costs to our customers in the next 2-3 quarters," said Gulati.

Also Read: Prefer auto ancillary, CV space; bullish on private, select PSU banks: Kotak Securities

The company is undergoing a big expansion, which is expected to get completed by the end of 2022, he said. “We are the only company in the western world that is expanding capacity; there is no other capacity in the offing. So some of this money would be utilised for our capex and of course there will be incremental cash flow. We have already spent about more than Rs 600 crore on this and about Rs 500 crore will be spent this year,” he elaborated.

For the full interview, watch the accompanying video.

Catch all market updates here.

(Edited by : Sandeep Singh)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Mama's Creations Fiscal Q3 Earnings Decline, Revenue Increases; Shares Plunge After Hours
Mama's Creations Fiscal Q3 Earnings Decline, Revenue Increases; Shares Plunge After Hours
Dec 16, 2024
04:22 PM EST, 12/16/2024 (MT Newswires) -- Mama's Creations (MAMA) reported fiscal Q3 diluted earnings late Monday of $0.01 per share, down from $0.05 a year earlier. A single analyst surveyed by FactSet expected $0.03. Revenue for the quarter ended Oct. 31 was $31.5 million, up from $28.7 million a year earlier. Four analysts surveyed by FactSet expected $30 million....
Lyondellbasell Industries Insider Bought Shares Worth $380,300, According to a Recent SEC Filing
Lyondellbasell Industries Insider Bought Shares Worth $380,300, According to a Recent SEC Filing
Dec 16, 2024
04:17 PM EST, 12/16/2024 (MT Newswires) -- Robin W.T. Buchanan, Director, on December 13, 2024, executed a purchase for 5,000 shares in Lyondellbasell Industries ( LYB ) for $380,300. Following the Form 4 filing with the SEC, Buchanan has control over a total of 18,175 shares of the company, with 18,175 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1489393/000156218024008417/xslF345X05/primarydocument.xml ...
Merus Reports First Person Dosed in Mid-Stage Petosemtamab Trial
Merus Reports First Person Dosed in Mid-Stage Petosemtamab Trial
Dec 16, 2024
04:22 PM EST, 12/16/2024 (MT Newswires) -- Merus (MRUS) said Monday the first person has been dosed in its phase 2 trial assessing petosemtamab in heavily pretreated metastatic colorectal cancer. In preclinical CRC models, petosemtamab consistently demonstrates superior activity compared to cetuximab, a mainstay therapy in mCRC, said Merus Chief Technology Officer John de Kruif. ...
Paylocity Holding Insider Sold Shares Worth $4,138,007, According to a Recent SEC Filing
Paylocity Holding Insider Sold Shares Worth $4,138,007, According to a Recent SEC Filing
Dec 16, 2024
04:17 PM EST, 12/16/2024 (MT Newswires) -- Steven I Sarowitz, 10% Owner, Director, on December 12, 2024, sold 20,421 shares in Paylocity Holding ( PCTY ) for $4,138,007. Following the Form 4 filing with the SEC, Sarowitz has control over a total of 8,885,533 shares of the company, with 8,365,533 shares held directly and 520,000 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1591698/000159169824000427/xslF345X05/wk-form4_1734383554.xml...
Copyright 2023-2026 - www.financetom.com All Rights Reserved